NC
JAZZ icon

nVerses Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

nVerses Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275K Buy
+1,141
New +$250K 0.42% 70
2024
Q4 		– Sell
-2,600
Closed -$290K – 433
2024
Q3 		$290K Buy
+2,600
New +$285K 0.13% 248

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

nVerses Capital's JAZZ Position: Q2 2026 in Review

nVerses Capital opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 1,141 shares worth $275K. The stake represents 0.42% of the portfolio and ranks #70 among its holdings. This is a return to the name: nVerses Capital previously reported a position in JAZZ as recently as Q3 2024.

nVerses Capital first reported a position in JAZZ in Q3 2024 and has held it in 2 quarters since. The position peaked at $290K in Q3 2024. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • nVerses Capital held 1,141 shares of Jazz Pharmaceuticals worth $275K as of Q2 2026.
  • Jazz Pharmaceuticals was a new nVerses Capital position in Q2 2026.
  • Jazz Pharmaceuticals made up 0.42% of nVerses Capital's portfolio in Q2 2026, its #70 holding.
  • nVerses Capital first reported a position in Jazz Pharmaceuticals in Q3 2024 and has held it in 2 quarters since.
  • nVerses Capital's Jazz Pharmaceuticals position peaked at $290K in Q3 2024.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.